Opko Health, Inc.
🇨🇱Chile
- Country
- 🇨🇱Chile
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 3.9K
- Market Cap
- -
- Website
- http://www.opko.com
Clinical Trials
47
Active:0
Completed:37
Trial Phases
5 Phases
Phase 1:14
Phase 2:20
Phase 3:7
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (46 trials with phase data)• Click on a phase to view related trials
Phase 2
20 (43.5%)Phase 1
14 (30.4%)Phase 3
7 (15.2%)Not Applicable
4 (8.7%)Phase 4
1 (2.2%)Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
Phase 3
Terminated
- Conditions
- Chronic Kidney Disease stage3Chronic Kidney Disease stage4Vitamin d DeficiencySecondary Hyperparathyroidism
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05543928
- Locations
- 🇺🇸
Nationwide Childrens Hospital, Columbus, Ohio, United States
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
Phase 2
Completed
- Conditions
- CoronavirusSARS-CoV2 InfectionCOVID-19
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT04551911
- Locations
- 🇺🇸
OPKO Investigative Site, Omaha, Nebraska, United States
4Kscore Using Serum Stored Uncentrifuged
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT04130776
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients
Not Applicable
Completed
- Conditions
- CataractDry Eye Syndromes
- First Posted Date
- 2019-08-21
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04063644
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT03874013
- Locations
- 🇯🇵
Aichi Medical University Hospital, Nagakute, Aichi, Japan
🇯🇵Seirei Sakura Citizen Hospital, Sakura, Chiba, Japan
🇯🇵Hospital of the University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
No news found